Agreement signed as part of Ontario's life sciences trade mission to Israel
TEL AVIV and TORONTO (May 16, 2016) – BioLineRx Ltd. a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for 15 of Toronto's top academic institutions.
Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of start-up companies originating from MaRS Innovation's members to identify in-licensing, co-development or other ...
The University of Toronto Early-Stage Technology (UTEST) program's second cohort is coming to a close, with applications for a third cohort open until April 17.
The incubator program, a University of Toronto and MaRS Innovation joint partnership, helps affiliates of the university develop and commercialize their ideas. Successful applicants receive twelve months of mentoring to incubate their technology into a product, with access to immediate follow-on investment of up to $500,000 through MaRS Innovation. Access to provincial and federal funding resources is also available, ...